Day: November 17, 2022

Iconic, Sport-Inspired Lifestyle Brand Celebrates the Season with Colorful Outerwear and Giftable Sets

WEST PALM BEACH, Fla., Nov. 17, 2022 (GLOBE NEWSWIRE) — U.S. Polo Assn., the official brand of the United States Polo Association (USPA), has launched its iconic, sport-inspired Winter/Holiday Collection for 2022. Resulting in images and video used by U.S. Polo Assn. partners around the world, the brand’s global photoshoot took place in the snow-capped mountains of Lake Tahoe, an iconic destination for a winter vacation.

This season’s global photoshoot highlights models in their festive looks, showcasing U.S. Polo Assn.’s signature red, white, and blue stripe against fluffy, white blankets of snow. The crystal blue waters, snow-covered mountains, and frosted pine trees of Lake Tahoe accentuate the Winter/Holiday 2022 Collection. The U.S. Polo Assn. Collection is filled with outerwear, long-sleeved polo shirts, flannel layers, puffer jackets and vests, fleece separates, and even boots. The color palette for this collection is a refreshing mix of classic neutrals and colorful brights, perfect for both traveling or staying home for the holidays. Consumers can cozy up this winter in U.S. Polo Assn. and enjoy the beauty of the season in classic American style.

“The U.S. Polo Assn. Creative Team was able to capture the essence of a winter wonderland in our global photoshoot at iconic Lake Tahoe. These amazing images capture our authentic connection to the sport of polo through our product and are shared with our partners across 190 countries,” said J. Michael Prince, President and CEO of USPA Global Licensing, which manages the global, multi-billion-dollar U.S. Polo Assn. brand. “U.S. Polo Assn. looks forward to bringing the Winter/Holiday 2022 Collection to consumers just in time for the holiday season.”

Soft, comfortable silhouettes and touchable texture go beyond loungewear pieces and offer versatility to closet staples, such as U.S. Polo Assn.’s sweatshirts and sweaters in the newest collection. Incorporate layering into winter fashion by playing with solids and patterns to bring seasonal looks together with our iconic sport-inspired style. Fans of the brand can shop the Winter/Holiday 2022 Collection in stores and online around the world for men, women, and children.

“As consumers venture back out to shop for the holidays, we want to bring joy and cheer to the season by making a statement with bright and bold outerwear,” said Brian Kaminer, SVP of Brand and Product Development for the U.S. Polo Assn. brand. “Winter/Holiday 2022 offers a fresh take on classic American styling to consumers throughout the holidays and into the new year.”

U.S. Polo Assn. is known worldwide for its authentic, sport-inspired style and the brand’s signature red, white and blue stripe detail in each garment. The Winter/Holiday 2022 Collection follows suit, with bold and fresh assortments combining unique styling, high-quality fabrics, and seasonal comfort, including USPA Life apparel with sustainable elements.

About U.S. Polo Assn. and USPA Global Licensing Inc. (USPAGL)

U.S. Polo Assn. is the official brand of the United States Polo Association (USPA), the nonprofit governing body for the sport of polo in the United States and one of the oldest sports governing bodies, having been founded in 1890. With a multi-billion-dollar global footprint and worldwide distribution through some 1,200 U.S. Polo Assn. retail stores and thousands of department stores as well as sporting goods channels, independent retailers and e-commerce, U.S. Polo Assn. offers apparel for men, women, and children, as well as accessories and footwear in 190 countries worldwide. Today, U.S. Polo Assn. is ranked the 28th largest licensor in the world and within the top five sports licensors, according to License Global’s 2022 list of “Top Global Licensors.” Visit uspoloassnglobal.com.

USPA Global Licensing Inc. (USPAGL) is the for-profit subsidiary of the USPA and its exclusive worldwide licensor. USPAGL manages the global, multi-billion-dollar U.S. Polo Assn. brand and is the steward of the USPA’s intellectual properties, providing the sport with a long-term source of revenue. Through its subsidiary, Global Polo Entertainment (GPE), USPAGL also manages Global Polo TV, the world’s leading digital platform with polo and lifestyle content. In addition, USPAGL partners with ESPN and beIN Sports globally to share the sport of polo broadcasts on television and on-demand to millions of viewers around the world. For more polo content, visit globalpolo.com.

Contact Information:
Kaela Drake
PR & Communications Coordinator
kdrake@uspagl.com
+001.561.461.8596

Stacey Kovalsky
Senior Director, Global Communications
skovalsky@uspagl.com
+001.561.790.8036

Related Images

Image 1: U.S. Polo Assn.

U.S. Polo Assn.

This content was issued through the press release distribution service at Newswire.com.

Attachment

• U.S. Polo Assn.

GlobeNewswire Distribution ID 8698757

Experience Continues to Show CCM Therapy Addresses Clinical Need in Treating Heart Failure

MARLTON, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) — Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure, announced the 100th implant in China, signifying the opportunity for its innovative Optimizer® system delivering CCM® therapy in markets around the world. Cardiologist Prof. Guo Tao, Executive Director of Internal Medicine, Fuwai Cardiovascular Hospital, Yunnan Province, performed the 100th procedure and emphasized the role of this therapy in providing an option and hope to patients living with the debilitating reality of heart failure.

“It is quite a coincidental milestone for us that the 10th patient implanted in our center also happened to be the 100th patient treated in China. I have paid very close attention to CCM therapy for more than 20 years now, but it wasn’t until recently we could clinically apply this technology. Under close clinical observation, our 10 CCM patients have improved even more than we anticipated. All the CCM patients in our center improved both symptomatically and on various objective indicators, which made both us and our patients very happy. Therefore, it seems from our experience that CCM is performing exactly as described in the foreign research — specifically, by modulating the exchange of calcium ions and thereby enhancing contractility of the myocardium in the acute period, then normalizing the expression of contraction-related proteins, which leads to reverse remodeling of the heart. Based on these results, we are now planning to expand the application of CCM normatively and actively while continuing to closely follow our implanted patients to obtain more clinical evidence of CCM to optimize its application so more Chinese patients can benefit from this latest innovative treatment.”

Prof. Zhang Shu, Chief Physician of Fuwai Hospital of the National Center for Cardiovascular Diseases and the Chinese Academy of Medical Sciences, Honorary Chairman of the Electrocardiology and Pacing Branch of the Chinese Medical Association, Director of the Cardiology Committee of the Chinese Medical Doctor Association, and former President of the Asia-Pacific Heart Rhythm Society further commented “Currently there are almost nine million patients with heart failure in China, and many of them have not been optimally treated. Heart failure has also become the leading cause of death among cardiovascular and other major chronic diseases in China. I believe CCM will bring good news to Chinese patients. These successful initial experiences provide our doctors with good prospects of bringing hope to the patients they care for.”

“We are proud to see the growing acceptance of this technology in markets around the world,” said Mateusz Zelewski, MD, Impulse Dynamics´ VP International. “In reaching this milestone, we have connected with physicians, patients, and their families. We are inspired by the benefits of this therapy to our patients and continue to reinforce our commitment to address the immense need for advanced heart failure options for patients around the world.”

CCM therapy was approved in China late last year, and the first implant in the country was announced on November 1, 2021. The Optimizer system delivers CCM therapy, which consists of electric pulses applied to the heart between heartbeats and serves to enhance the performance of cardiac muscular contraction, making the heart work more efficiently without increasing the heart rate or the oxygen consumption of the cardiac muscle.

To date, CCM therapy has been used to treat heart failure in more than 7,000 patients worldwide and is available in 44 countries across the globe. The therapy has been studied in almost 2,000 patients and has appeared in more than 100 peer-reviewed journal articles. Ongoing studies are also underway to examine the safety and efficacy of CCM for patients suffering from heart failure with a left ventricular ejection fraction between 40 – 60 percent.

About Impulse Dynamics

Impulse Dynamics is dedicated to helping healthcare providers enhance the lives of people with heart failure by transforming how the condition is treated. The company is focused on delivering its proprietary CCM therapy, which is delivered by the company’s Optimizer device, the CE-marked, and FDA-approved treatment verified to improve the quality of life for heart failure patients. CCM therapy is a safe, effective, and minimally invasive treatment option for many heart failure patients who otherwise have few effective options available to them.[1] To learn more, visit www.ImpulseDynamics.com, or follow the company on LinkedIn, Twitter, and Facebook.

Forward-looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘anticipate,’’ ‘‘could,’’ ‘‘intend,’’ ‘‘target,’’ ‘‘project,’’ ‘‘contemplate,’’ ‘‘believe,’’ ‘‘estimate,’’ ‘‘predict,’’ ‘‘potential’’ or ‘‘continue’’ or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning potential benefits of CCM therapy, and the absence of risks associated therewith; the ability for CCM therapy and our products to fill a significant unmet medical need for patients with heart failure; and the short-term and long-term benefits of the Optimizer and CCM therapy in patients with heart failure, as well as to the physicians treating those patients. These forward-looking statements are based on management’s current expectations and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Other important factors that could cause actual results, performance or achievements to differ materially from those contemplated in this press release include, without limitation: the company’s future research and development costs, capital requirements and the company’s needs for additional financing; commercial success and market acceptance of CCM therapy; the company’s ability to achieve and maintain adequate levels of coverage or reimbursement for Optimizer systems or any future products the company may seek to commercialize; competitive companies and technologies in the industry; the company’s ability to expand its indications and develop and commercialize additional products and enhancements to its current products; the company’s business model and strategic plans for its products, technologies and business, including its implementation thereof; the company’s ability to expand, manage and maintain its direct sales and marketing organization; the company’s ability to commercialize or obtain regulatory approvals for CCM therapy and its products, or the effect of delays in commercializing or obtaining regulatory approvals; FDA or other U.S. or foreign regulatory actions affecting us or the healthcare industry generally, including healthcare reform measures in the United States and international markets; the timing or likelihood of regulatory filings and approvals; and the company’s ability to establish and maintain intellectual property protection for CCM therapy and products or avoid claims of infringement. The company does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein. These forward-looking statements should not be relied upon as representing the company’s views as of any date subsequent to the date of this press release.

[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494150/

Attachments

• Optimizer® Smart Mini System
• Optimizer® Smart Mini System

Rohan More, Global VP of Marketing
Impulse Dynamics
856-642-9933
rmore@impulsedynamics.com

Harris Currie, Chief Financial Officer (Investor Relations)
Impulse Dynamics
856-642-9933
hcurrie@impulsedynamics.com

Ian Ségal, Public Relations
Impulse Dynamics
856-642-9933
isegal@impulsedynamics.com

GlobeNewswire Distribution ID 8698682

London, November 16, 2022

CNH Industrial N.V. (NYSE: CNHI / MI: CNHI) today announces the appointment of Vilmar Fistarol as President, North America and Rafael Miotto as President, Latin America.

Vilmar Fistarol will lead the North America region as of late January 2023, following over a decade as President, Latin America, during which time he has continually grown CNH Industrial’s brands’ sales in the region to market leading positions. Vilmar has served CNH Industrial and its predecessor companies for over 31 years in numerous leadership positions. He replaces Brad Crews, whose upcoming transition to a new role in the Agriculture Segment was announced in September 2022.

Rafael Miotto will assume responsibility for the Latin America region as of January 2023, and this appointment will see him join the Company’s Senior Leadership Team. Rafael has successfully led the New Holland Agriculture brand in Latin America for the last five years, and in his 18 years with the company has gained extensive experience in sales and marketing, aftersales and commercial operations.

“CNH Industrial is focused on delivering for our customers, the world’s farmers and builders. In Vilmar and Rafael we have two proven leaders, who are committed to driving ever greater success in two key regions for the agriculture and construction businesses,” said Scott W. Wine, Chief Executive Officer, CNH Industrial. “I am confident they will drive significant value for our customers, dealers and all stakeholders.”

CNH Industrial (NYSE: CNHI / MI: CNHI) is a world-class equipment and services company. Driven by its purpose of Breaking New Ground, which centers on Innovation, Sustainability and Productivity, the Company provides the strategic direction, R&D capabilities, and investments that enable the success of its global and regional Brands. Globally, Case IH and New Holland Agriculture supply 360° agriculture applications from machines to implements and the digital technologies that enhance them; and CASE and New Holland Construction Equipment deliver a full lineup of construction products that make the industry more productive. The Company’s regionally focused Brands include: STEYR, for agricultural tractors; Raven, a leader in digital agriculture, precision technology and the development of autonomous systems; Flexi-Coil, specializing in tillage and seeding systems; Miller, manufacturing application equipment; Kongskilde, providing tillage, seeding and hay & forage implements; and Eurocomach, producing a wide range of mini and midi excavators for the construction sector, including electric solutions. Across a history spanning over two centuries, CNH Industrial has always been a pioneer in its sectors and continues to passionately innovate and drive customer efficiency and success. As a truly global company, CNH Industrial’s 37,000+ employees form part of a diverse and inclusive workplace, focused on empowering customers to grow, and build, a better world.

For more information and the latest financial and sustainability reports visit: cnhindustrial.com

For news from CNH Industrial and its Brands visit: media.cnhindustrial.com

Media contacts:

Rebecca Fabian	Anna Angelini
North America	United Kingdom
Tel. +1 312 515 2249	Tel. +44 (0)7725 826 007

mediarelations@cnhind.com

Attachment

• 20221116_PR_CNH_Industrial_SLT_Announcements

GlobeNewswire Distribution ID 1000757314